First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

Kim-Son H Nguyen, Joel W NealStanford Cancer Institute, Stanford University, Stanford, CA, USAAbstract: Epidermal growth factor&ndash;receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC)....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nguyen KS, Neal JW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/df50be203eb746cd82bc4f08172f2614
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:df50be203eb746cd82bc4f08172f2614
record_format	dspace
spelling	oai:doaj.org-article:df50be203eb746cd82bc4f08172f26142021-12-02T02:53:07ZFirst-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors1177-54751177-5491https://doaj.org/article/df50be203eb746cd82bc4f08172f26142012-09-01T00:00:00Zhttp://www.dovepress.com/first-line-treatment-of-egfr-mutant-non-small-cell-lung-cancer-the-rol-a11109https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Kim-Son H Nguyen, Joel W NealStanford Cancer Institute, Stanford University, Stanford, CA, USAAbstract: Epidermal growth factor&ndash;receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC). Subsequent studies, including IPASS, OPTIMAL, and EURTAC, have demonstrated that these TKIs are effective first-line therapeutic options in patients with tumors harboring activating mutations in the EGFR gene. The TKIs are better tolerated than conventional chemotherapy, with frequent yet mild side effects such as rash and diarrhea, and rarely interstitial lung disease. Because most patients on TKIs develop resistance due to a variety of mechanisms, the use of TKIs in the acquired-resistance setting and in the setting of earlier-staged cancers is being extensively studied. Here we review the major trials leading to the established use of EGFR TKIs in NSCLC, followed by discussion of recently completed and ongoing trials using the next-generation EGFR inhibitor afatinib.Keywords: epidermal growth factor receptor, non-small-cell lung cancer, tyrosine kinase inhibitor, epidermal growth factor&ndash;receptor mutationNguyen KSNeal JWDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 337-345 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Nguyen KS Neal JW First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
description	Kim-Son H Nguyen, Joel W NealStanford Cancer Institute, Stanford University, Stanford, CA, USAAbstract: Epidermal growth factor&ndash;receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC). Subsequent studies, including IPASS, OPTIMAL, and EURTAC, have demonstrated that these TKIs are effective first-line therapeutic options in patients with tumors harboring activating mutations in the EGFR gene. The TKIs are better tolerated than conventional chemotherapy, with frequent yet mild side effects such as rash and diarrhea, and rarely interstitial lung disease. Because most patients on TKIs develop resistance due to a variety of mechanisms, the use of TKIs in the acquired-resistance setting and in the setting of earlier-staged cancers is being extensively studied. Here we review the major trials leading to the established use of EGFR TKIs in NSCLC, followed by discussion of recently completed and ongoing trials using the next-generation EGFR inhibitor afatinib.Keywords: epidermal growth factor receptor, non-small-cell lung cancer, tyrosine kinase inhibitor, epidermal growth factor&ndash;receptor mutation
format	article
author	Nguyen KS Neal JW
author_facet	Nguyen KS Neal JW
author_sort	Nguyen KS
title	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_short	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_full	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_fullStr	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_full_unstemmed	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
title_sort	first-line treatment of egfr-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/df50be203eb746cd82bc4f08172f2614
work_keys_str_mv	AT nguyenks firstlinetreatmentofegfrmutantnonsmallcelllungcancertheroleoferlotinibandothertyrosinekinaseinhibitors AT nealjw firstlinetreatmentofegfrmutantnonsmallcelllungcancertheroleoferlotinibandothertyrosinekinaseinhibitors
_version_	1718402074226458624

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

Ejemplares similares